AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11444499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (0.1 mg/kg) administered during cardiopulmonary bypass
Number of subjects: 70
Study 11444499 — intervention group
Group type: COMPARATOR
Intervention: No nicorandil (control group)
Number of subjects: 70
Study 9924680 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions per week
Number of subjects: 20
Study 9924680 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions per week
Number of subjects: 20
Study 9924680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7997395 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin tablets
Number of subjects: 6
Study 7997395 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin capsules
Number of subjects: 6
Study 7997395 — intervention group
Group type: COMPARATOR
Intervention: Control (tablets)
Number of subjects: 6
Study 7997395 — intervention group
Group type: COMPARATOR
Intervention: Control (capsules)
Number of subjects: 6
Study 29373382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannequin-based simulation
Number of subjects: 84
Study 29373382 — intervention group
Group type: COMPARATOR
Intervention: Virtual simulation
Number of subjects: 84
Study 26764884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir therapy with peginterferon and ribavirin
Number of subjects: 600
Study 26764884 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon and ribavirin only
Number of subjects: 600
Study 24862701 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 100
Study 24862701 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 100
Study 23252003 — intervention group
Group type: EXPERIMENTAL
Intervention: HTESB therapy
Number of subjects: 40
Study 23252003 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 20521323 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 20521323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19008269 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including named coordinating centre staff, prompt identification and resolution of logistic problems, varying volume of invitations, using local non‐attendance rates, and organizing large ad hoc clinics.
Number of subjects: 202638
Study 19008269 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial management and planning strategies.
Number of subjects: 202638
Study 19008269 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to participate in the trial.
Number of subjects: 202638
Study 19008269 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment scheduling for recruitment.
Number of subjects: 202638
Study 17183628 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent antiretroviral therapy (ART)
Number of subjects: 101
Study 17183628 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment HIV-1 RNA levels
Number of subjects: 101
Study 14504915 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/week of methotrexate
Number of subjects: 46
Study 14504915 — intervention group
Group type: COMPARATOR
Intervention: 2 g/day of sulphasalazine
Number of subjects: 46
Study 10714732 — intervention group
Group type: EXPERIMENTAL
Intervention: Real bipolar permanent magnets
Number of subjects: 20
Study 10714732 — intervention group
Group type: COMPARATOR
Intervention: Sham bipolar permanent magnets
Number of subjects: 20
Study 9186834 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 77
Study 9186834 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 77
Study 8232869 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 G needle
Number of subjects: 113
Study 8232869 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 G needle
Number of subjects: 113
Study 8232869 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 113
Study 8232869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 113
Study 8232869 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelogram type
Number of subjects: 113
Study 8232869 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelographer
Number of subjects: 113
Study 3986068 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia (local anaesthetics from before skin incision until 24 h after skin incision plus extradural morphine 4 mg every 12 h from 3 h to 72 h after skin incision)
Number of subjects: 20
Study 3986068 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with low‐dose fentanyl plus intermittent systemic morphine for postoperative pain
Number of subjects: 20
Study 31295161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg q.d. for 4 weeks
Number of subjects: 34
Study 31295161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30328976 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion pump A at 100 mL/h
Number of subjects: 0
Study 30328976 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion pump A at 300 mL/h
Number of subjects: 0
Study 30328976 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion pump B at 100 mL/h
Number of subjects: 0
Study 30328976 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion pump B at 300 mL/h
Number of subjects: 0
Study 26947800 — intervention group
Group type: EXPERIMENTAL
Intervention: EDACS‐ADP
Number of subjects: 558
Study 26947800 — intervention group
Group type: COMPARATOR
Intervention: ADAPT‐ADP
Number of subjects: 558
Study 26947800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 558
Study 24606836 — intervention group
Group type: EXPERIMENTAL
Intervention: MCA and IRT (LLRA model)
Number of subjects: 381
Study 24606836 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA
Number of subjects: 381
Study 21614461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse A (experimental amine fluoride/stannous fluoride)
Number of subjects: 0
Study 21614461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse B (experimental amine fluoride/stannous fluoride)
Number of subjects: 0
Study 21614461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse C (phenolic/essential oil rinse)
Number of subjects: 0
Study 21614461 — intervention group
Group type: COMPARATOR
Intervention: Rinse D (negative control, water rinse)
Number of subjects: 0
Study 20177360 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS events
Number of subjects: 9583
Study 20177360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious non-AIDS (SNA) events
Number of subjects: 9583
Study 17604892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (participation in a 4 month programme of intergenerational activities)
Number of subjects: 519
Study 17604892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 519
Study 15601806 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human albumin (rHA)
Number of subjects: 530
Study 15601806 — intervention group
Group type: COMPARATOR
Intervention: Human serum albumin (HSA)
Number of subjects: 530
Study 15601806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of rHA
Number of subjects: 530
Study 15601806 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of HSA
Number of subjects: 530
Study 15601806 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human albumin (rHA) and Human serum albumin (HSA)
Number of subjects: 530
Study 12189224 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 320
Study 12189224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 10457510 — intervention group
Group type: EXPERIMENTAL
Intervention: Males: 70-lb bench press, standing long jump, and agility
Number of subjects: 48
Study 10457510 — intervention group
Group type: EXPERIMENTAL
Intervention: Females: Agility and 1.5-mile endurance run
Number of subjects: 48
Study 10457510 — intervention group
Group type: COMPARATOR
Intervention: Males: Agility
Number of subjects: 48
Study 7794983 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based arthritis education program (6 weekly sessions of 2.5 hours' duration)
Number of subjects: 175
Study 7794983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 2130666 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment
Number of subjects: 34
Study 2130666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 376054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg daily for six weeks
Number of subjects: 54
Study 376054 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone sodium 300 mg daily for one week then 150 mg daily for five weeks
Number of subjects: 54
Study 376054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 54
Study 376054 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone sodium
Number of subjects: 54
Study 31112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg per day for 4 weeks)
Number of subjects: 2500
Study 31112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin combined with azithromycin
Number of subjects: 2500
Study 31112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin and azithromycin combination
Number of subjects: 2500
Study 28068121 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Motivational Enhancement Therapy delivered in Spanish
Number of subjects: 405
Study 25807939 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg daily dose of delayed-release prednisone
Number of subjects: 350
Study 25807939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 24516413 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (2,000 mg/day for up to 20 intravenous infusions followed by 1,200 mg/day orally)
Number of subjects: 500
Study 24516413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 21414452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 69
Study 21414452 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational (PE) seminar
Number of subjects: 69
Study 20136957 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC)
Number of subjects: 1413
Study 20136957 — intervention group
Group type: COMPARATOR
Intervention: Conventional contrast-assisted cannulation
Number of subjects: 1413
Study 18037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40, 60, 80, 120 mg/day)
Number of subjects: 2463
Study 18037817 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (10 mg/day escitalopram, 20 mg/day fluoxetine and paroxetine)
Number of subjects: 2463
Study 18037817 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2463
Study 15239013 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous threaded cylindrical bone (Unilab Surgibone)
Number of subjects: 44
Study 15239013 — intervention group
Group type: COMPARATOR
Intervention: Titanium implant (Bak‐C; Spine‐Tech, Minneapolis)
Number of subjects: 44
Study 10958599 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2) given as a short infusion prior to cisplatin
Number of subjects: 31
Study 10958599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 31
Study 9048415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐min audiotaped persuasive message about BBTD
Number of subjects: 120
Study 9048415 — intervention group
Group type: EXPERIMENTAL
Intervention: Same audiotaped message with overheard audience response affirming the message
Number of subjects: 120
Study 9048415 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 120
Study 7687940 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple elastic knee sleeve
Number of subjects: 84
Study 7687940 — intervention group
Group type: COMPARATOR
Intervention: Elastic knee sleeve with silicone patellar ring
Number of subjects: 84
Study 7687940 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 84
Study 3576126 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg)
Number of subjects: 17
Study 3576126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30285503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bang Pre‐Workout Master Blaster (BMB)
Number of subjects: 10
Study 30285503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 31564137 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 0
Study 31564137 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 0
Study 28157653 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository + vaginal cream + oral vitamin B complex (group C)
Number of subjects: 158
Study 28157653 — intervention group
Group type: COMPARATOR
Intervention: Suppository + oral antifungal agents (group A)
Number of subjects: 158
Study 28157653 — intervention group
Group type: COMPARATOR
Intervention: Suppository + vaginal cream (group B)
Number of subjects: 158
Study 28157653 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B complex (various dosages in mice)
Number of subjects: 158
Study 28157653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (in vitro with vitamin B complex)
Number of subjects: 158
Study 26446482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose soy (HDS) - 2 soy muffins containing 25 g soy protein
Number of subjects: 243
Study 26446482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose soy (LDS) - 1 soy and 1 wheat muffin containing 12.5 g soy protein and 12.5 g whey protein
Number of subjects: 243
Study 26446482 — intervention group
Group type: COMPARATOR
Intervention: Control - 2 wheat muffins containing 25 g whey protein
Number of subjects: 243
Study 26446482 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HDS, LDS, Control)
Number of subjects: 243
Study 24026038 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (n = 280)
Number of subjects: 563
Study 24026038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 283)
Number of subjects: 563
Study 21670457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of depot hydroxyprogesterone 500 mg 5 to 14 days before surgery
Number of subjects: 1000
Study 21670457 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 1000
Study 18814804 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat modified sham feeding (MSF)
Number of subjects: 14
Study 17098421 — intervention group
Group type: EXPERIMENTAL
Intervention: pviFOX (oxaliplatin plus protracted infusion of 5‐fluorouracil)
Number of subjects: 118
Study 17098421 — intervention group
Group type: COMPARATOR
Intervention: XELOX (oxaliplatin plus capecitabine)
Number of subjects: 118
Study 15301775 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-copers
Number of subjects: 3
Study 15301775 — intervention group
Group type: EXPERIMENTAL
Intervention: Copers
Number of subjects: 3
Study 15301775 — intervention group
Group type: COMPARATOR
Intervention: Uninjured subjects
Number of subjects: 3
Study 11294041 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 116
Study 11294041 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (30 mg/day)
Number of subjects: 116
Study 9447285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol diphosphate (DES‐DP)
Number of subjects: 36
Study 9447285 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LH‐RH agonist: LHRH‐A)
Number of subjects: 36
Study 7940142 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine
Number of subjects: 0
Study 7940142 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% pilocarpine
Number of subjects: 0
Study 7940142 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 0
Study 7940142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% p‐amino‐clonidine
Number of subjects: 0
Study 7940142 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in normal volunteers
Number of subjects: 0
Study 7940142 — intervention group
Group type: COMPARATOR
Intervention: OHT subjects (compared to normal controls)
Number of subjects: 0
Study 7940142 — intervention group
Group type: COMPARATOR
Intervention: LTG and RD subjects (compared to normal controls)
Number of subjects: 0
Study 3344599 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 12
Study 3344599 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 12
Study 29689636 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU started 1 minute after SonoVue injection
Number of subjects: 102
Study 29689636 — intervention group
Group type: COMPARATOR
Intervention: HIFU started 10 minutes after SonoVue injection
Number of subjects: 102
Study 27704865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic massage (Sahacharadi Taila) for 2 weeks (6 hours total)
Number of subjects: 64
Study 27704865 — intervention group
Group type: COMPARATOR
Intervention: Local thermal therapy for 2 weeks
Number of subjects: 64
Study 27704865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic massage (Sahacharadi Taila)
Number of subjects: 64
Study 27704865 — intervention group
Group type: COMPARATOR
Intervention: Local thermal therapy
Number of subjects: 64
Study 26759297 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 µm glycine powder air-polishing (GPAP)
Number of subjects: 23
Study 26759297 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling
Number of subjects: 23
Study 24294709 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt surgical needles
Number of subjects: 240
Study 24294709 — intervention group
Group type: COMPARATOR
Intervention: Sharp surgical needles
Number of subjects: 240
Study 21711204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg Avena sativa herb extract
Number of subjects: 36
Study 21711204 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Avena sativa herb extract
Number of subjects: 36
Study 21711204 — intervention group
Group type: COMPARATOR
Intervention: 2400 mg Avena sativa herb extract
Number of subjects: 36
Study 19704269 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 59
Study 19704269 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard fine mesh gauze dressing)
Number of subjects: 59
Study 16923836 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Web site providing educational material about organ donation and transplantation
Number of subjects: 490
Study 16923836 — intervention group
Group type: COMPARATOR
Intervention: Control Web site providing educational material on methods to avoid the common cold
Number of subjects: 490
Study 15558393 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month, twice-weekly exercise program (n = 11)
Number of subjects: 21
Study 15558393 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising controls (n = 10)
Number of subjects: 21
Study 11375232 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical guidelines disseminated to general practices in the intervention arm.
Number of subjects: 689
Study 11375232 — intervention group
Group type: COMPARATOR
Intervention: Control practices that received clinical guidelines one year later.
Number of subjects: 689
Study 9236555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular immune serum globulin (4 mL of 16% polyvalent immune serum globulin every 2 months, n = 450)
Number of subjects: 899
Study 9236555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 449)
Number of subjects: 899
Study 8353585 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial line sample with discard volume deadspace
Number of subjects: 30
Study 8353585 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial line sample with discard volume deadspace + 2 mL
Number of subjects: 30
Study 8353585 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial line sample with discard volume deadspace + 4 mL
Number of subjects: 30
Study 8353585 — intervention group
Group type: COMPARATOR
Intervention: Venous control samples
Number of subjects: 30
Study 3226848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 10)
Number of subjects: 26
Study 3226848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with cognitive strategy instructions (n = 16)
Number of subjects: 26
Study 29714501 — intervention group
Group type: EXPERIMENTAL
Intervention: DEsCT with ASIS technique and reduced iodine load (Group B2)
Number of subjects: 62
Study 29714501 — intervention group
Group type: EXPERIMENTAL
Intervention: DEsCT with ASIS technique and reduced iodine load (Group B)
Number of subjects: 62
Study 29714501 — intervention group
Group type: COMPARATOR
Intervention: Conventional 120-kVp CT (Group A)
Number of subjects: 62
Study 27273731 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/d)
Number of subjects: 71
Study 27273731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 26594287 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI) intervention group
Number of subjects: 33
Study 26594287 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 22927665 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 402
Study 22927665 — intervention group
Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 402
Study 20628153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 0
Study 18977978 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to Care Questionnaire scores
Number of subjects: 252
Study 18977978 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a regular doctor
Number of subjects: 252
Study 18977978 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having experienced foregone care
Number of subjects: 252
Study 22338850 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless technique (FL)
Number of subjects: 9